Therapeutic Drug Monitoring in Neonates: What Makes them Unique?

Area of Science:

• Pharmacology
• Neonatal Medicine
• Clinical Chemistry

Background:

• Therapeutic drug monitoring (TDM) involves analyzing drug concentrations to optimize efficacy and minimize toxicity.
• Neonatal TDM shares principles with adult TDM but presents unique challenges.
• Key issues include pharmacokinetic variability, non-PK factors, sampling limitations, analytical methods, and therapeutic ranges.

Purpose of the Study:

• To review the specific issues relevant to TDM in neonates.
• To discuss the implications of pharmacokinetic variability and non-PK factors on drug concentration interpretation.
• To explore advancements in sampling techniques and analytical methods for neonatal TDM.

Main Methods:

• Review of existing literature on TDM in neonatal populations.
• Discussion of pharmacokinetic and non-pharmacokinetic factors influencing drug levels.
• Evaluation of analytical techniques and alternative sampling methods.

Main Results:

• Neonates exhibit greater pharmacokinetic variability and differing endogenous substance levels compared to adults, complicating TDM.
• Population PK-models and Bayesian forecasting can aid in dose individualization.
• Dried blood spot sampling and saliva analysis offer less invasive alternatives.
• Therapeutic ranges are often extrapolated from adult data, potentially misaligning with neonatal pharmacodynamics.

Conclusions:

• Neonatal TDM requires tailored approaches due to unique physiological and analytical challenges.
• Further research is recommended to establish specific neonatal therapeutic ranges and optimize TDM strategies.
• Advancements in analytical techniques and sampling methods are improving the feasibility of neonatal TDM.